Endocrine Abstracts

Contents

• 14th Annual Meeting of the UK and Ireland Neuroendocrine Tumour Society 2016
• • Speaker Abstracts
  • What's new in NETs? ENETS guidelines update (new recommendations applied to interactive cases), UK epidemiology and genetics
  • • (Guidelines) update on small bowel NETs

      ea0046nets1
    • Abstract unavailable

      ea0046nets2
    • Bronchial NETs

      ea0046nets3
    • Abstract unavailable

      ea0046nets4
    • Where NETs fit in with the 100,000 genome project

      ea0046nets5
  • Management of Phaeochromocytoma/Paraganglioma
  • • Abstract unavailable

      ea0046nets6
    • Abstract unavailable

      ea0046nets7
    • Abstract unavailable

      ea0046nets8
  • Open clinical session
  • • UK survey on the use of long-acting somatostatin analogues in neuroendocrine tumours

      ea0046nets9
    • An exploration of psychological symptoms in patients with vasoactive hormone-secreting neuroendocrine tumours (carcinoid syndrome)

      ea0046nets10
  • Translational Science Session
  • • Abstract unavailable

      ea0046nets11
    • Abstract unavailable

      ea0046nets12
  • International Speaker & Trials update
  • • Abstract unavailable

      ea0046nets13
    • Abstract unavailable

      ea0046nets14
• Oral Communications
• • (1)
  • • Netazepide, a gastrin/CCK2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis

      ea0046oc1
    • Tumour size is not a reliable criterion for management of patients with Non-secreting pancreatic neuroendocrine tumours: results of a large, multi-centre, operative cohort

      ea0046oc2
    • Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period

      ea0046oc3
• Poster Presentations
• • (1)
  • • MicroRNAs associated with small bowel neuroendocrine tumours and their metastases

      ea0046p1
    • 68Gallium-DOTANOC (68Ga-DOTANOC) positron emission tomography (PET) imaging in Bronchial Carcinoids (BC): multicentre evaluation of its role in clinical practice

      ea0046p2
    • Health-related quality of life (HRQoL), anxiety, depression and impulsivity in patients with advanced Gastroenteropancreatic Neuroendocrine Tumours (GEPNETs)

      ea0046p3
    • Measurement of urinary 5-hydroxyindole acetic acid: correlation between spot versus 24-hour urine collection

      ea0046p4
    • Incidence and characteristics of Ileo-colonic neuroendocrine tumours identified in the UK bowel cancer screening programme

      ea0046p5
    • Whole-exome next generation sequencing of sporadic adrenocortical carcinomas - evidence for a proposed adenoma-carcinoma carcinogenesis sequence

      ea0046p6
    • Evaluation of quality of life after each cycle in patients treated with Peptide Receptor Radionuclide Therapy (PRRT)

      ea0046p7
    • Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies

      ea0046p8
    • Whole-exome sequencing (WES) of samples from patients with advanced pancreatic neuroendocrine tumours (pNETs) with exceptional responses vs. poor responders to targeted therapies; a TransNET study

      ea0046p9
    • Biomarkers for carcinoid heart disease

      ea0046p10
    • Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews

      ea0046p11
    • Evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells (CTCs) in patients with neuroendocrine tumours (NET)

      ea0046p12
    • Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis

      ea0046p13
    • Perioperative carcinoid crisis during surgery-who benefits from octreotide?

      ea0046p14
    • Low rate of psychological ill health in patients with GEP NETS attending an ENETS Centre of Excellence

      ea0046p15
    • Knockdown of Gα15 in BON cell line enhances pancreastatin inhibitory effect on neoplastic proliferation

      ea0046p16
    • UK Phase IV, Observational study to assess Quality of Life in patients (pts) with pancreatic neuroendocrine tumours (pNETs) receiving treatment with Everolimus: The “Real-World” OBLIQUE Study

      ea0046p17
    • High-grade neuroendocrine tumours of the oesophagus: a single centre experience

      ea0046p18
    • Patient outcomes after cardiac surgery for carcinoid heart disease are dependant upon successful cytoreductive multimodal treatment and control of metastatic neuroendocrine disease

      ea0046p19
    • Initial experience of a novel technique for endoscopic full thickness resection of rectal neuroendocrine tumours

      ea0046p20
    • Efficacy of the combination of Capecitabine and Temozolamide in patients with advanced Pulmonary Carcinoid Tumors: A single institution experience

      ea0046p21
    • Multivisceral transplantation and vascularised sentinel forearm flap for a metastatic small bowel neuroendocrine tumour: Update on follow-up

      ea0046p22
    • Evaluation of faecal elastase 1 in symptomatic patients with neuroendocrine tumours

      ea0046p23
    • Improving outcomes for patients with resectable small bowel NET tumours; 5 year experience from a tertiary centre

      ea0046p24
    • Prognostic factors that mandate long term follow up following surgery for appendix neuroendocrine tumours (aNETs)

      ea0046p25
    • The use of continuous glucose monitoring to investigate and manage a rare cause of spontaneous hypoglycaemia

      ea0046p26
    • Modality to detect pancreatic NETS in MEN1: EUS or MRI?

      ea0046p27
    • Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: a case-matched analysis

      ea0046p28
    • Succinate dehydrogenase subunit-B mutation with associated prolactinoma and typical carcinoids

      ea0046p29
    • Evaluating the impact of the Specialist Nurse

      ea0046p30
    • A single centre analysis of the management of appendiceal neuroendocrine neoplasms (NENs) including goblet cell carcinoids (GCC)

      ea0046p31
    • Orbital neuroendocrine tumor metastases: diversity of presentation

      ea0046p32
    • A case report of bicaval stents and inferior vena cava valve implantation to control carcinoid symptoms in order to safely allow surgical valve replacement

      ea0046p33
    • An exploration of psychological symptoms in vasoactive hormone-secreting neuroendocrine tumours (carcinoid syndrome)

      ea0046p34
    • Cardiac metastases from ileal NETs

      ea0046p35